U.S. Pfizer is unlikely to come back with a fresh bid for AstraZeneca, the Anglo-Swedish pharmaceuticals group's top executive was quoted as saying by Swedish business daily Dagens Industri on Saturday.
Breaking News
Pfizer (PFE.N) dampened investors' expectations of a renewed bid for AstraZeneca (AZN.L) on Monday by signing a major cancer drug deal with Germany's Merck KGaA (MRCG.DE), reducing the U.S. firm's need for Astra's products.
Recent U.S. tax changes have weakened the case for companies like Pfizer (PFE.N) to shift their tax bases overseas by striking so-called tax inversion deals, according to AstraZeneca's (AZN.L) chief executive.
Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa.
AstraZeneca's cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.
Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector.
Shares in drugmakers AstraZeneca (AZN.L) and Shire (SHP.L) both fell more than 5 percent on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad.
U.S. fund managers are finding a lot to like about finger-painting and naptime. Fund ownership of Bright Horizons Family Solutions Inc, the only publicly traded daycare company in the United States, swelled 21 percent in the most recently reported quarter according to fund tracker Morningstar.
Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.
Oklahoma, US-based anti-abortion craft store chain Hobby Lobby stirred controversy by investing $73 million in Pfizer, Bayer, and other companies that make abortive drugs and contraception.
After lackluster activity in the past years, pharmaceutical firms have gotten back to producing new drugs but they encounter challenges in selling them, according to a report on The Wall Street Journal.
Ben Venue Laboratories, a subsidiary of German Boehringer Ingelheim in the US, has engaged Bank of American Merill Lynch to advise it on a proposed sale of its sterile injectable drugs business.
Merck & Co. decided to cut its annual spending by USD2.5 billion and eliminate more than 10% of its global workers.
Pharmaceutical giants Pfizer, AstraZeneca and Novartis are among those to propose bids for Onyx Pharmaceuticals.
Pfizer invests in two plants in Ireland.
